A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Phase 2
1,160
about 2.4 years
40+
86 sites in AL, AZ, CA +25
About this study
Researchers are testing a treatment called AZD6793 compared to a placebo (inactive pill) in people with moderate to very severe COPD. The trial will last for 861 days and involve approximately 1160 participants.
Based on ClinicalTrials.gov records.
What participants do
- 1.Placebo
- 2.Take AZD6793
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Secondary: Change from baseline in Breathlessness, Cough and Sputum Scale (BCSS) total score, Change from baseline in COPD Assessment Test (CAT) total score, Change from baseline in St George's Respiratory Questionnaire (SGRQ) total and domain scores, Change from baseline in post-bronchodilator (post-BD) forced expiratory volume in 1 second (FEV1), Change from baseline in pre-bronchodilator (pre-BD) forced expiratory volume in 1 second (FEV1)
Respiratory